Savara's Molgramostim Shows Exercise Capacity Gains in aPAP Trial

Event summary

  • Savara presented new exercise capacity data from the IMPALA-2 Phase 3 trial of molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP) at the ATS 2026 International Conference.
  • Molgramostim-treated patients showed a 167.0-meter improvement in distance walked at Week 48, compared to 86.4 meters for placebo (P=0.0301).
  • Exercise duration increased by 2.0 minutes in the molgramostim group versus 1.0 minute in the placebo group (P=0.0262).
  • The trial met its primary endpoint and secondary endpoints, including peak METs improvement.

The big picture

Savara's positive IMPALA-2 data strengthens molgramostim's profile as a potential first-line treatment for aPAP, a rare lung disease with limited therapeutic options. The results align with broader industry trends toward targeted therapies for orphan respiratory conditions, where clinical efficacy and functional improvements are key differentiators. The next critical step will be navigating regulatory approvals and preparing for commercialization in a niche but high-unmet-need market.

What we're watching

Regulatory Pathway
Whether the IMPALA-2 data will support a successful regulatory submission for molgramostim in aPAP.
Commercial Viability
The potential real-world functional benefits of molgramostim and its impact on patient quality of life.
Competitive Landscape
How Savara positions molgramostim against emerging therapies for rare respiratory diseases.